Zacks Research Upgrades Keros Therapeutics (NASDAQ:KROS) to Strong-Buy

Keros Therapeutics (NASDAQ:KROS) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Monday, Zacks reports.

Several other brokerages have also recently weighed in on KROS. Wall Street Zen raised shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Tuesday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Finally, Leerink Partners decreased their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $21.40.

Keros Therapeutics Stock Performance

Shares of KROS stock opened at $9.33 on Monday. Keros Therapeutics has a fifty-two week low of $8.98 and a fifty-two week high of $22.55. The firm has a market capitalization of $183.05 million, a P/E ratio of -3.31 and a beta of 1.13. The stock’s fifty day moving average is $11.11 and its two-hundred day moving average is $11.82.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.96) by $1.66. The firm had revenue of $40.01 million for the quarter, compared to analyst estimates of $14.76 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.85%. On average, equities analysts forecast that Keros Therapeutics will post -4.45 earnings per share for the current year.

Keros Therapeutics declared that its Board of Directors has approved a stock repurchase program on Wednesday, September 9th that authorizes the company to buy back $5 million in shares. This repurchase authorization authorizes the company to reacquire up to 2.3% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Keros Therapeutics

In related news, insider Lorena Raquel Lerner sold 3,568 shares of Keros Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the sale, the insider owned 27,559 shares in the company, valued at approximately $283,582.11. This trade represents a 11.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 5,343 shares of company stock worth $54,985. Company insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KROS. Diversified Trust Co purchased a new stake in shares of Keros Therapeutics in the 3rd quarter valued at $133,000. Squarepoint Ops LLC purchased a new position in shares of Keros Therapeutics in the second quarter valued at approximately $334,000. Hsbc Holdings PLC grew its holdings in shares of Keros Therapeutics by 29.5% in the second quarter. Hsbc Holdings PLC now owns 69,926 shares of the company’s stock valued at $761,000 after purchasing an additional 15,940 shares in the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Keros Therapeutics in the second quarter valued at approximately $15,091,483. Finally, Empowered Funds LLC purchased a new stake in Keros Therapeutics during the 2nd quarter worth approximately $1,521,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

More Keros Therapeutics News

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target while raising its 2026 and 2027 earnings estimates. Separately, Zacks said KROS’s roughly 21% decline over four weeks had pushed it into oversold territory, which could leave room for a rebound if selling pressure eases. Zacks article
• Neutral Sentiment: A report listed short interest at zero shares and a zero-day short-interest ratio. The figure offers little indication of short-selling pressure, though it conflicts with the entry’s description of a large increase.
• Negative Sentiment: Keros is still forecast to report losses, and HC Wainwright trimmed its 2028–2030 earnings estimates. Those revisions point to ongoing uncertainty about the pace of the company’s path to profitability.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function. Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.